Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 5Leukemia, Myeloid, Acute 3Uveal Melanoma 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leiomyosarcoma 1HER2 Negative Metastatic Breast Cancer 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

Doxorubicin 33pembrolizumab 16Gemcitabine 15eribulin 10Irinotecan 10olaratumab 9Trabectedin 9pazopanib 8Docetaxel 8Injections 7Cyclophosphamide 7Nivolumab 6Fluorouracil 6anlotinib 5Temozolomide 5Ipilimumab 5Ifosfamide 5Bevacizumab 5tazemetostat 4ridaforolimus 4Drug Therapy 4Cetuximab 4Carboplatin 4toripalimab 3surufatinib 3spartalizumab 3ganitumab 3entrectinib 3conatumumab 3belinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma × ADI PEG20 × Clear all
NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡